JY
NWBO

Jeff Yass’s Northwest Biotherapeutics, Inc. Common stock NWBO Stock Holding History

Jeff Yass’s Portfolio NWBO Stock Details NWBO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-186,083
Closed -$101K – 10725
2016
Q3 		$101K Sell
186,083
-176,169
-49% -$80.5K ﹤0.01% 7939
2016
Q2 		$211K Buy
362,252
+13,980
+4% +$14.9K ﹤0.01% 7531
2016
Q1 		$508K Buy
348,272
+121,286
+53% +$239K ﹤0.01% 6371
2015
Q4 		$726K Sell
226,986
-534,714
-70% -$2.57M ﹤0.01% 6061
2015
Q3 		$4.76M Buy
761,700
+81,404
+12% +$761K ﹤0.01% 2739
2015
Q2 		$6.75M Buy
680,296
+451,209
+197% +$3.95M ﹤0.01% 2495
2015
Q1 		$1.69M Buy
229,087
+144,213
+170% +$970K ﹤0.01% 4646
2014
Q4 		$454K Sell
84,874
-173,582
-67% -$888K ﹤0.01% 7409
2014
Q3 		$1.3M Sell
258,456
-4,168
-2% -$25.6K ﹤0.01% 5418
2014
Q2 		$1.76M Buy
262,624
+50,144
+24% +$319K ﹤0.01% 4898
2014
Q1 		$1.54M Buy
212,480
+140,805
+196% +$835K ﹤0.01% 4756
2013
Q4 		$270K Buy
+71,675
New +$277K ﹤0.01% 7761

Other funds holding NWBO

WIM
Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return
CDH
Charles D. Hyman $1.79B AUM 17.18% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return
MBT
Montecito Bank & Trust Santa Barbara, California $668M AUM 24.84% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return
BW
Biegel & Waller Columbia, Maryland $179M AUM 1.6% 1-Year Est. Return
MPI
Mairs & Power Inc St Paul, Minnesota $10.9B AUM 27.5% 1-Year Est. Return

Jeff Yass's NWBO Position: Q4 2016 in Review

Jeff Yass sold out of Northwest Biotherapeutics, Inc. Common stock (NWBO) in Q4 2016, closing a stake of 186,083 shares — an estimated $101K sold.

Jeff Yass first reported a position in NWBO in Q4 2013 and held it in 12 quarters. The position peaked at $6.75M in Q2 2015. 8 funds tracked by Wall St. Rank hold NWBO as of Q4 2016.

  • Jeff Yass reported no remaining Northwest Biotherapeutics, Inc. Common stock position as of Q4 2016 after selling out during the quarter.
  • Jeff Yass sold 186,083 Northwest Biotherapeutics, Inc. Common stock shares in Q4 2016, an estimated $101K.
  • Jeff Yass first reported a position in Northwest Biotherapeutics, Inc. Common stock in Q4 2013 and held it in 12 quarters.
  • Jeff Yass's Northwest Biotherapeutics, Inc. Common stock position peaked at $6.75M in Q2 2015.
  • 8 funds tracked by Wall St. Rank held Northwest Biotherapeutics, Inc. Common stock as of Q4 2016.

Based on Susquehanna International Group's 13F filing for Q4 2016, filed 14 Feb 2017.